Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.

Algarín EM, Díaz-Tejedor A, Mogollón P, Hernández-García S, Corchete LA, San-Segundo L, Martín-Sánchez M, González-Méndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Gutiérrez NC, Mateos MV, Paíno T, Garayoa M, Ocio EM.

Haematologica. 2019 Jul 18. pii: haematol.2018.212308. doi: 10.3324/haematol.2018.212308. [Epub ahead of print]

2.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Jun 25. doi: 10.1007/s00277-019-03739-2. [Epub ahead of print]

PMID:
31240472
3.

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Paul B, Lipe B, Ocio EM, Usmani SZ.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e176-e186. doi: 10.1200/EDBK_238527. Epub 2019 May 17.

PMID:
31099624
4.

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.

Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK.

Leukemia. 2019 May 15. doi: 10.1038/s41375-019-0482-0. [Epub ahead of print]

PMID:
31092894
5.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J.

Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15946. [Epub ahead of print] No abstract available.

PMID:
31090915
6.

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA.

Biol Blood Marrow Transplant. 2019 May 3. pii: S1083-8791(19)30282-4. doi: 10.1016/j.bbmt.2019.04.026. [Epub ahead of print]

PMID:
31054983
7.

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Nuñez-Córdoba JM, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Puig N, Oriol A, Paiva B, Bladé J, Lahuerta JJ, San Miguel JF.

Blood Cancer J. 2019 Mar 18;9(4):36. doi: 10.1038/s41408-019-0176-x.

8.

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, Miguel JFS.

Leukemia. 2019 Apr;33(4):1056. doi: 10.1038/s41375-019-0408-x.

PMID:
30846864
9.

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.

Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, Moreno C, Vidriales MB, Toboso DG, Cedena MT, Ocio EM, Lecumberri R, García de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Pérez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Prosper F, Martinez-Lopez J, Lecrevisse Q, Verde J, Mateos MV, Lahuerta JJ, Orfao A, San Miguel JF.

Leukemia. 2019 May;33(5):1256-1267. doi: 10.1038/s41375-018-0308-5. Epub 2018 Dec 12.

PMID:
30542145
10.

Aggressive primary cutaneous CD30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin.

Cañueto J, Ocio EM, Román-Curto C.

Int J Dermatol. 2018 Dec;57(12):e153-e155. doi: 10.1111/ijd.14214. Epub 2018 Sep 7. No abstract available.

PMID:
30191555
11.

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.

Qian X, Dimopoulos MA, Amatangelo M, Bjorklund C, Towfic F, Flynt E, Weisel KC, Ocio EM, Yu X, Peluso T, Sternas L, Zaki M, Moreau P, Thakurta A.

Leuk Lymphoma. 2019 Feb;60(2):462-470. doi: 10.1080/10428194.2018.1485915. Epub 2018 Aug 2.

PMID:
30068263
12.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J.

Haematologica. 2018 Nov;103(11):e544-e548. doi: 10.3324/haematol.2018.188839. Epub 2018 Jun 28. No abstract available.

13.

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF.

Leukemia. 2018 Nov;32(11):2427-2434. doi: 10.1038/s41375-018-0072-6. Epub 2018 Feb 23. Erratum in: Leukemia. 2019 Apr;33(4):1056.

PMID:
29515235
14.

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.

Hernández-García S, San-Segundo L, González-Méndez L, Corchete LA, Misiewicz-Krzeminska I, Martín-Sánchez M, López-Iglesias AA, Algarín EM, Mogollón P, Díaz-Tejedor A, Paíno T, Tunquist B, Mateos MV, Gutiérrez NC, Díaz-Rodriguez E, Garayoa M, Ocio EM.

Haematologica. 2017 Dec;102(12):2113-2124. doi: 10.3324/haematol.2017.168666. Epub 2017 Aug 31.

15.

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.

Rojas EA, Corchete LA, San-Segundo L, Martínez-Blanch JF, Codoñer FM, Paíno T, Puig N, García-Sanz R, Mateos MV, Ocio EM, Misiewicz-Krzeminska I, Gutiérrez NC.

Clin Cancer Res. 2017 Nov 1;23(21):6602-6615. doi: 10.1158/1078-0432.CCR-17-0678. Epub 2017 Aug 8.

16.

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

López-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, González-Méndez L, Hernández-García S, Misiewicz-Krzeminska I, Quwaider D, Martín-Sánchez M, Primo D, Paíno T, Bergsagel PL, Mehrling T, González-Díaz M, San-Miguel JF, Mateos MV, Gutiérrez NC, Garayoa M, Ocio EM.

J Hematol Oncol. 2017 Jun 20;10(1):127. doi: 10.1186/s13045-017-0495-y.

17.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
18.

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

González-Calle V, Cerdá S, Labrador J, Sobejano E, González-Mena B, Aguilera C, Ocio EM, Vidriales MB, Puig N, Gutiérrez NC, García-Sanz R, Alonso JM, López R, Aguilar C, de Coca AG, Hernández R, Hernández JM, Escalante F, Mateos MV.

Haematologica. 2017 May;102(5):922-931. doi: 10.3324/haematol.2016.158345. Epub 2017 Jan 25.

19.

Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case.

González-Calle V, Jorge-Finnigan C, Santos-Durán JC, López-Cadenas F, Ocio EM, García-Sanz R, Santos-Briz Á, Fernández-López E, San Miguel J, Mateos MV, Román-Curto C.

Clin Case Rep. 2016 Oct 11;4(12):1096-1100. eCollection 2016 Dec.

20.

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.

Fernández de Larrea C, Dávila J, Isola I, Ocio EM, Rosiñol L, García-Sanz R, Cibeira MT, Tovar N, Rovira M, Mateos MV, Miguel JS, Bladé J.

Bone Marrow Transplant. 2017 Apr;52(4):567-569. doi: 10.1038/bmt.2016.299. Epub 2016 Nov 21.

PMID:
27869809
21.

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.

López-Iglesias AA, González-Méndez L, San-Segundo L, Herrero AB, Hernández-García S, Martín-Sánchez M, Gutiérrez NC, Paíno T, Avilés P, Mateos MV, San-Miguel JF, Garayoa M, Ocio EM.

Haematologica. 2017 Jan;102(1):168-175. doi: 10.3324/haematol.2016.146076. Epub 2016 Aug 18.

22.

The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.

Paíno T, Garcia-Gomez A, González-Méndez L, San-Segundo L, Hernández-García S, López-Iglesias AA, Algarín EM, Martín-Sánchez M, Corbacho D, Ortiz-de-Solorzano C, Corchete LA, Gutiérrez NC, Maetos MV, Garayoa M, Ocio EM.

Clin Cancer Res. 2017 Jan 1;23(1):225-238. doi: 10.1158/1078-0432.CCR-16-0230. Epub 2016 Jul 20.

23.

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.

Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P.

Blood. 2016 Jul 28;128(4):497-503. doi: 10.1182/blood-2016-02-700872. Epub 2016 May 25.

24.

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV.

Leukemia. 2016 Oct;30(10):2026-2031. doi: 10.1038/leu.2016.123. Epub 2016 May 2.

PMID:
27133826
25.

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.

Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF; Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups.

Blood. 2016 Jun 23;127(25):3165-74. doi: 10.1182/blood-2016-03-705319. Epub 2016 Apr 26.

26.

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.

Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D; Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO).

Br J Haematol. 2016 Apr;173(2):245-52. doi: 10.1111/bjh.13945. Epub 2016 Feb 5.

PMID:
26847165
27.

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF; Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Groups.

Blood. 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679. Epub 2016 Jan 11.

28.

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.

Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J.

Blood. 2016 Jan 28;127(4):420-5. doi: 10.1182/blood-2015-08-666537. Epub 2015 Oct 23.

29.

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.

Ocio EM, Herrera P, Olave MT, Castro N, Pérez-Simón JA, Brunet S, Oriol A, Mateo M, Sanz MÁ, López J, Montesinos P, Chillón MC, Prieto-Conde MI, Díez-Campelo M, González M, Vidriales MB, Mateos MV, San Miguel JF; PETHEMA Group.

Haematologica. 2015 Oct;100(10):1294-300. doi: 10.3324/haematol.2015.129577. Epub 2015 Jul 9.

30.

Treatment for patients with newly diagnosed multiple myeloma in 2015.

Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez-López J, Bladé J, Lahuerta JJ, García-Sanz R, San Miguel JF.

Blood Rev. 2015 Nov;29(6):387-403. doi: 10.1016/j.blre.2015.06.001. Epub 2015 Jun 12. Review.

PMID:
26094881
31.

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV; Spanish Myeloma Group (GEM/PETHEMA).

Haematologica. 2015 Sep;100(9):1207-13. doi: 10.3324/haematol.2015.128439. Epub 2015 Jun 11.

32.

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.

Ocio EM, Oriol A, Bladé J, Teruel AI, Martín J, de la Rubia J, Gutiérrez NC, Rodríguez Díaz-Pavón J, Martínez González S, Coronado C, Fernández-García EM, Siguero Gómez M, Fernández-Teruel C, San Miguel J.

Br J Haematol. 2016 Feb;172(4):625-8. doi: 10.1111/bjh.13515. Epub 2015 Jun 2. No abstract available.

PMID:
26033438
33.

Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.

Ocio EM, Dávila J, Caballero JC, Alonso S, de la Calle VG, García-Sanz R, Gazi L, Opio S, Jiménez M, San-Miguel JF, Mateos MV.

Haematologica. 2015 Jul;100(7):e289-91. doi: 10.3324/haematol.2015.124164. Epub 2015 Mar 20. No abstract available.

34.

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma.

Paiva B, Azpilikueta A, Puig N, Ocio EM, Sharma R, Oyajobi BO, Labiano S, San-Segundo L, Rodriguez A, Aires-Mejia I, Rodriguez I, Escalante F, de Coca AG, Barez A, San Miguel JF, Melero I.

Leukemia. 2015 Oct;29(10):2110-3. doi: 10.1038/leu.2015.79. Epub 2015 Mar 17. No abstract available.

PMID:
25778100
35.

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

Paiva B, Corchete LA, Vidriales MB, García-Sanz R, Perez JJ, Aires-Mejia I, Sanchez ML, Barcena P, Alignani D, Jimenez C, Sarasquete ME, Mateos MV, Ocio EM, Puig N, Escalante F, Hernández J, Cuello R, García de Coca A, Sierra M, Montes MC, González-López TJ, Galende J, Bárez A, Alonso J, Pardal E, Orfao A, Gutierrez NC, San Miguel JF.

Blood. 2015 Apr 9;125(15):2370-80. doi: 10.1182/blood-2014-09-602565. Epub 2015 Feb 5.

36.

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.

Paíno T, Paiva B, Sayagués JM, Mota I, Carvalheiro T, Corchete LA, Aires-Mejía I, Pérez JJ, Sanchez ML, Barcena P, Ocio EM, San-Segundo L, Sarasquete ME, García-Sanz R, Vidriales MB, Oriol A, Hernández MT, Echeveste MA, Paiva A, Blade J, Lahuerta JJ, Orfao A, Mateos MV, Gutiérrez NC, San-Miguel JF.

Leukemia. 2015 May;29(5):1186-94. doi: 10.1038/leu.2014.321. Epub 2014 Nov 12.

PMID:
25388955
37.

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

Paiva B, Chandia M, Puig N, Vidriales MB, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, Lahuerta JJ, Mateos MV, San Miguel JF.

Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7. No abstract available.

38.

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A.

Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. No abstract available.

39.

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Garcia-Gomez A, De Las Rivas J, Ocio EM, Díaz-Rodríguez E, Montero JC, Martín M, Blanco JF, Sanchez-Guijo FM, Pandiella A, San Miguel JF, Garayoa M.

Oncotarget. 2014 Sep 30;5(18):8284-305.

40.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG.

Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25242045
41.

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, García-Gómez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF.

Leukemia. 2015 Mar;29(3):705-14. doi: 10.1038/leu.2014.238. Epub 2014 Aug 8.

PMID:
25102946
42.

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma.

Paiva B, Chandia M, Vidriales MB, Colado E, Caballero-Velázquez T, Escalante F, Garcia de Coca A, Montes MC, Garcia-Sanz R, Ocio EM, Mateos MV, San Miguel JF.

Blood. 2014 Aug 21;124(8):1300-3. doi: 10.1182/blood-2014-04-567909. Epub 2014 May 29.

43.

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.

Paíno T, Sarasquete ME, Paiva B, Krzeminski P, San-Segundo L, Corchete LA, Redondo A, Garayoa M, García-Sanz R, Gutiérrez NC, Ocio EM, San-Miguel JF.

PLoS One. 2014 Mar 21;9(3):e92378. doi: 10.1371/journal.pone.0092378. eCollection 2014.

44.

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hernández-Iglesias T, Martens AC, Groen RW, Mateo-Urdiales J, Fraile S, Galarraga M, Chauhan D, San Miguel JF, Raje N, Garayoa M.

Clin Cancer Res. 2014 Mar 15;20(6):1542-54. doi: 10.1158/1078-0432.CCR-13-1657. Epub 2014 Jan 31.

45.

Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.

Chen X, Díaz-Rodríguez E, Ocio EM, Paiva B, Mortensen DS, Lopez-Girona A, Chopra R, Miguel JS, Pandiella A.

Mol Cancer Ther. 2014 Feb;13(2):504-16. doi: 10.1158/1535-7163.MCT-13-0022. Epub 2014 Jan 15.

46.

Future agents and treatment directions in multiple myeloma.

Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC.

Expert Rev Hematol. 2014 Feb;7(1):127-41. doi: 10.1586/17474086.2014.858595. Epub 2013 Dec 18. Review.

47.

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF.

Leukemia. 2014 Mar;28(3):525-42. doi: 10.1038/leu.2013.350. Epub 2013 Nov 20. Review.

48.

Novel generation of agents with proven clinical activity in multiple myeloma.

Mateos MV, Ocio EM, San Miguel JF.

Semin Oncol. 2013 Oct;40(5):618-33. doi: 10.1053/j.seminoncol.2013.07.005. Review.

PMID:
24135407
49.

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.

Paiva B, Paino T, Sayagues JM, Garayoa M, San-Segundo L, Martín M, Mota I, Sanchez ML, Bárcena P, Aires-Mejia I, Corchete L, Jimenez C, Garcia-Sanz R, Gutierrez NC, Ocio EM, Mateos MV, Vidriales MB, Orfao A, San Miguel JF.

Blood. 2013 Nov 21;122(22):3591-8. doi: 10.1182/blood-2013-06-510453. Epub 2013 Sep 26.

50.

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group.

Leukemia. 2013 Oct;27(10):2056-61. doi: 10.1038/leu.2013.166. Epub 2013 Jun 7. Erratum in: Leukemia. 2013 Oct;27(10):2112.

PMID:
23743858

Supplemental Content

Loading ...
Support Center